Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular

• Autor(a) principal: Moura, Soraia Santana de
• Data de Publicação: 2012
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/6958
• topic: Análise toxicológica; Derivado pirazolínico; Fármaco cardiovascular; Toxicological analysis; Pyrazole derivative; Cardiovascular drug; FARMACIA::ANALISE TOXICOLOGICA

Cardiovascular diseases are among the diseases of higher mortality rates in Brazil and worldwide . In contrast, it is reducing deaths of cardiovascular diseases due, in large part, to the production of drugs that can control their risk factors, but the wide reporting of side effects and contraindications persist and interfere negatively in the context of mortality these diseases. In this point, it is necessary to develop new drugs more effective and safer. The process of development of new drug requires numerous preclinical studies that generate information regarding safety profile in vivo determinants for making the decision to start clinical trials. Although it is a conventional practice, the use of animals in scientific research should happen consciously, always considering the ethical issues of animal experimentation. In this study, we investigated the basal cytotoxicity against 3T3 cells of seven pyrazole compounds (LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024) and classified then in GHS system. Whereas the compound LQFM021 proved to be the most effective in the tests performed in parallel pharmacodynamic study, we investigated whether acute oral toxicity, subacute and mutagenicity of this compound. The results showed that the compounds have low cytotoxicity profile in basal cell line (3T3). The estimated LD50 values for compounds LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024 were 548, 551, 568, 533, 457, 482, 565 mg / kg, respectively. The compounds LQFM020, LQFM023 LQFM024 were classified in category 5 GHS system and LQFM021 was classified in category 4. The subacute toxicological research for 28 days LQFM021 the compound showed that this compound did not affect the metabolic, hematological and biochemical animal parameters in any of the doses of exposure However, the histopathology indicated hepatotoxic and nephrotoxic potential of this compound and interference in the process of hematopoiesis, but did not indicate mutagenic potential. . Given the above, we conside